Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $19000.0.

  • Coherus Oncology's Gains from Investment Securities fell 9392.97% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year decrease of 8099.78%. This contributed to the annual value of $28.7 million for FY2024, which is 2132.73% up from last year.
  • As of Q3 2025, Coherus Oncology's Gains from Investment Securities stood at $19000.0, which was down 9392.97% from $43000.0 recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Gains from Investment Securities ranged from a high of $2.8 million in Q1 2023 and a low of $10000.0 during Q4 2024
  • Its 5-year average for Gains from Investment Securities is $687705.9, with a median of $326000.0 in 2023.
  • Per our database at Business Quant, Coherus Oncology's Gains from Investment Securities surged by 358260.87% in 2022 and then crashed by 9693.25% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Gains from Investment Securities stood at $23000.0 in 2021, then soared by 3582.61% to $847000.0 in 2022, then plummeted by 61.51% to $326000.0 in 2023, then crashed by 96.93% to $10000.0 in 2024, then soared by 90.0% to $19000.0 in 2025.
  • Its Gains from Investment Securities stands at $19000.0 for Q3 2025, versus $43000.0 for Q2 2025 and $267000.0 for Q1 2025.